|1.||Shulkes, Arthur: 13 articles (05/2015 - 09/2002)|
|2.||Baldwin, Graham S: 11 articles (05/2015 - 09/2002)|
|3.||Wang, Timothy C: 10 articles (04/2015 - 05/2003)|
|4.||Varro, Andrea: 8 articles (07/2014 - 08/2002)|
|5.||Stieber, Petra: 7 articles (08/2012 - 09/2006)|
|6.||Singh, Pomila: 7 articles (04/2012 - 08/2002)|
|7.||Reubsaet, Léon: 6 articles (12/2014 - 01/2013)|
|8.||Paus, Elisabeth: 6 articles (07/2014 - 11/2007)|
|9.||Ferrand, Audrey: 5 articles (04/2012 - 04/2005)|
|10.||Jin, Guangchun: 4 articles (04/2015 - 09/2009)|
09/01/1990 - "Proper gastrinoma tissue contained several precursor forms, including intact unprocessed progastrin. "
01/01/1989 - "In the two gastrinoma cultures, RIA determinations and electron microscopic observations indicated that the proportion of progastrin increased with time while that of G17 and G34 decreased. "
12/15/1988 - "Two forms of human progastrin isolated from a gastrinoma were separated by ion-exchange h.p.l.c., and had similar elution positions on reverse-phase h.p.l.c. "
02/01/1986 - "The results suggest differences in posttranslational processing pathways of progastrin in antrum, duodenum, and gastrinomas. "
02/01/1986 - "Identification of progastrin in gastrinomas, antrum, and duodenum by a novel radioimmunoassay."
04/01/2011 - "Study on biodistribution and radioimmunoimaging of (131)iodine-labeled monoclonal antibody D-D3 against progastrin-releasing peptide31-98 in tumor-bearing mouse."
03/01/2007 - "The association between progastrin, progastrin-derived processing intermediates and colorectal carcinogenesis has also been examined through genetic or chemical cancer induction in several mouse models, although the clinical relevance of these studies still remains to be proven. "
01/01/2006 - "The association between progastrin, progastrin-derived processing intermediates and colorectal carcinogenesis has also been examined through genetic or chemical cancer induction in several mouse models, although the clinical relevance of these studies remains unproven. "
07/01/2013 - "We investigated whether progastrin affects signaling between colonic epithelial and myofibroblast compartments to regulate tissue homeostasis and cancer susceptibility. "
06/01/2012 - "A strong association between plasma pro-gastrin-releasing peptide (pro-GRP) level and tumor Bcl-2 copy number (R = 0.93) was confirmed. "
|3.||Chronic Kidney Failure (Chronic Renal Failure)
07/01/1996 - "The highest serum pro-gastrin-releasing peptide levels in patients with chronic renal failure, before and after initiating haemodialysis were 183 and 290 ng/l respectively. "
07/01/1996 - "In contrast, 14 or 16 patients (88%) with small-cell lung carcinoma, who had normal renal function, and 25 of 26 (96%) patients with chronic renal failure on haemodialysis had serum pro-gastrin-releasing peptide concentrations greater than 46 ng/l. "
12/01/1980 - "Although the peak postprandial increment in big gastrin concentration in 11 chronic renal failure patients (34.0+/-7.5 pM) was significantly greater (p < 0.05) than in 25 normal subjects (19.5+/-4.6 pM), the little gastrin responses were not significantly different. "
12/01/1980 - "As circulating little gastrin is six times more potent than big gastrin in stimulating acid secretion, these studies suggest that the raised gastrin concentrations observed in patients with chronic renal failure have little significance in terms of their increased incidence of duodenal ulcer disease."
07/01/1996 - "Pro-gastrin-releasing peptide concentrations in sera from normal subjects and patients with small-cell lung carcinoma, diabetes mellitus, rheumatoid arthritis, systemic lupus erythematosus, chronic glomerulonephritis, or undialysed or dialysed chronic renal failure were measured with the TND-4 Kit, a newly developed ELISA for pro-gastrin-releasing peptide. "
01/15/2015 - "hGAS mice, which overexpress progastrin in the liver, and mice of the corresponding wild-type FVB/N strain were exposed to normoxia or hypoxia. "
01/15/2015 - "The aim of this study was to determine if higher concentrations of the gastrin precursor progastrin are protective against hypoxia in vivo. "
01/15/2015 - "This is the first report of an association between progastrin overexpression, hypoxia, and iron homeostasis."
01/15/2015 - "We conclude that increased circulating concentrations of progastrin provide a physiological advantage against systemic hypoxia in mice, possibly by increasing the availability of iron stores. "
|5.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/28/2014 - "Peptide imprinted receptors for the determination of the small cell lung cancer associated biomarker progastrin releasing peptide."
06/01/2011 - "Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis."
01/01/2007 - "Serum progastrin-releasing peptide levels followed by whole-body positron emission tomography detects early recurrence of small-cell lung cancer."
11/01/2001 - "Here we measured serum levels of pro-gastrin-releasing peptide (Pro-GRP), a more stable precursor of GRP, in 15 patients with MTC (4 males, 11 females) who did not show any clinical or radiologic signs of small cell lung cancer. "
01/01/1999 - "Serum pro-gastrin-releasing peptide is a useful marker for treatment monitoring and survival in small-cell lung cancer."
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|5.||Interleukin-8 (Interleukin 8)
|9.||pro-gastrin-releasing peptide (31-98)
|10.||Phosphopyruvate Hydratase (Enolase)
|2.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)